ClinConnect ClinConnect Logo
Search / Trial NCT04003311

MDR - Comprehensive Primary/Micro Stem & Versa-Dial Ti Humeral Head

Launched by ZIMMER BIOMET · Jun 26, 2019

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

The objective of this retrospective/prospective enrollment and prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,2,3,5,7 and 10 years\*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinic...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Study devices must have been implanted following the surgical technique and IFU for the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads
  • Patient must be 18 years of age or older.
  • * Patient must have undergone a primary or revision shoulder arthroplasty with the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads for a cleared indication. Cleared indications include the following:
  • non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis,
  • rheumatoid arthritis,
  • revision where other devices or treatments have failed,
  • correction of functional deformity,
  • fractures of the proximal humerus where other methods of treatment are deemed inadequate,
  • difficult clinical management problems including cuff arthroplasty where other treatment methods may not be suitable or may be inadequate.
  • Exclusion Criteria:
  • Absolute contraindications include infection, sepsis, and osteomyelitis.
  • * Relative contraindications include:
  • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
  • Patient is a prisoner.
  • Patient is a current alcohol or drug abuser.
  • Patient is known to be pregnant or breastfeeding.
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent.

About Zimmer Biomet

Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.

Locations

Rochester, New York, United States

Rochester, New York, United States

Royal Oak, Michigan, United States

Boise, Idaho, United States

Burlington, Vermont, United States

York, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Erin Osborn

Study Director

Zimmer Biomet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials